Payment overview · 2025
General Payments
$146.11
7 reported records · 6 companies
Healthcare provider profile · identity verified
Emily Schroeder, M.D., PH.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · FORT WAYNE, IN · NPI 1306021118
Verified facts
What the public records show
CMS Open Payments records show Emily Schroeder, M.D., PH.D. received $146.11 in general payments during 2025 across 7 reported records.
Madrigal Pharmaceuticals accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $33.73 | 23.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.74 | 19.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.40 | 16.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.84 | 15.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.89 | 15.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.51 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.11 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 110 |
| Mounjaro | Tirzepatide | 192 | 35 |
| Metformin Hcl Er | Metformin Hcl | 99 | 33 |
| Methimazole | Methimazole | 87 | 26 |
| Metformin Hcl | Metformin Hcl | 81 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 74 | 22 |
| Ozempic | Semaglutide | 70 | 27 |
| Jardiance | Empagliflozin | 59 | 14 |
| Synthroid | Levothyroxine Sodium | 59 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 52 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 19 |
| Hydrocortisone | Hydrocortisone | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | 14 |
| Glimepiride | Glimepiride | 34 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Omnitrope | Somatropin | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lisinopril | Lisinopril | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.11 · 7 records | Madrigal Pharmaceuticals | CRENESSITY, FREESTYLE LIBRE 3, INPEN SMART INSULIN DELIVERY SYSTEM, Korlym, REZDIFFRA, TEPEZZA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error